Setmelanotide

Overview

Setmelanotide is a protein active pharmaceutical ingredient (ChEMBL CHEMBL3301624).

Patent & exclusivity (US)

Per the FDA Orange Book (1 approved US product), the latest listed US patent on Setmelanotide expires 4 Jul 2034 and exclusivity 20 Dec 2031. Generic API sourcing typically opens up once these lapse.

Chemical identity

IUPAC name

(4R,7S,10S,13R,16S,19R,22R)-22-[[(2S)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-13-benzyl-10-[3-(diaminomethylideneamino)propyl]-16-(1H-imidazol-5-ylmethyl)-7-(1H-indol-3-ylmethyl)-19-methyl-6,9,12,15,18,21-hexaoxo-1,2-dithia-5,8,11,14,17,20-hexazacyclotricosane-4-carboxamide

Canonical SMILES

C[C@@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)C)C(=O)N)CC2=CNC3=CC=CC=C32)CCCN=C(N)N)CC4=CC=CC=C4)CC5=CN=CN5

InChIKey

HDHDTKMUACZDAA-PHNIDTBTSA-N